The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Keytruda, the biggest product in Merck’s portfolio, generated sales of $7.43 billion in the quarter, up 21%. Sales of the drug benefited from rapid uptake across earlier-stage indications in ...

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Disruptive analytics’s Substack by Magnus Ofstad. In this ...

Welcome to the Merck & Company Q3 sales and earnings conference call. [Operator instructions] This call is being recorded.

Merck (MRK) will be in focus as company beats revenue forecasts despite in line earnings amid strong Keytruda sales in Q3 ...

Merck and Co. (NYSE: MRK) has posted better-than-anticipated third-quarter profit thanks to solid demand for its crucial ...

Pfizer has the FDA approval it was seeking for Prevnar 20, the latest update to its blockbuster pneumococcal vaccination franchise, keeping it one step ahead of a competing shot from Merck & Co.

Merck & Co. is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Merck lowered guidance for 2024 adjusted earnings per share to the ...

Merck (MRK) came out with quarterly earnings of $1.57 per share, beating the Zacks Consensus Estimate of $1.50 per share. This compares to earnings of $2.13 per share a year ago. These figures are ...

Merck KGaA and Pfizer have got the fourth checkpoint ... with fewer than half of patients surviving more than a year and fewer than 20% surviving beyond five years. Further confirmatory data ...

Investing.com -- Merck (NS:PROR) and Co. (NYSE:MRK) has posted better-than-anticipated third ... Meanwhile, the company narrowed its full-year sales forecast, citing a solid growth and new product ...